NDAORALTABLET
Approved
Oct 2008
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
4/8 — Partial
LOSEASONIQUE (levonorgestrel/ethinyl estradiol and ethinyl estradiol) by Teva is ovulation. First approved in 2008.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOSEASONIQUE is an oral combined hormonal contraceptive containing levonorgestrel and ethinyl estradiol in a extended-cycle regimen designed to reduce menstrual frequency. It prevents pregnancy by suppressing ovulation and altering cervical mucus and endometrial conditions. The product targets women seeking effective contraception with fewer menstrual cycles.
LOE Approaching2.6 years to LOE
Product approaching loss of exclusivity with 2.6 years remaining; commercial teams should prepare transition strategies and focus on loyalty programs before generic erosion accelerates.
Mechanism of Action
ovulation.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on LOSEASONIQUE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.